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medicineJames Chien-Hsing Lin a, Qing-Dong Ling b,c, Matt Chang a,
Frank Chang a, Hsin-Chung Lee b,da Feng Chi Biotech Corp., Taipei, Taiwan
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Taiwan
c Cathay Medical Research Institute, Cathay General Hospital, Taipei, Taiwan
d Department of Surgery, Cathay General Hospital, Taipei, TaiwanBackground: Colorectal cancer (CRC) is one of the leading causes of cancer death around the world, and has become the
most common cancer in Taiwan since 2007. A mass of clinical researches, through comprehensive genomic approaches, had
highlighted the CRC genomic landscape complexity. Mutations and variants of these genomes are identified as prognostic
and/or predictive makers for CRC. A robust and cost-effect method to simultaneously characterize all clinical relevant
mutations and genomic variants is urgently needed for realization of personalized medicine. Two molecular testing panels
were designed and evaluated for the clinical applications of CRC cases in this study.
Materials and Methods: The gene mutation and DNA sequence profiles in 24 clinical CRC samples were analyzed using mass
spectrometry with two high-throughput procedures to screen for four and eight genes, respectively. One panel, named as
KBPC panel, was used to detect 53 mutations of KRAS, BRAF, PIK3CA and CTNNB1 genes for evaluation of target-therapies
and prognosis, and another panel, named as CRCPG panel, was used to genotype 12 variants of ABCG2, DPYD, ERCC1, GSTP1,
MTHFR, TYMS, UGT1A1 and XRCC1 genes for evaluation of the chemical-therapy dosages thus avoiding potential adverse
drug effects.
Results: The KBPC panel of the 24 clinical CRC samples: two samples with BRAF c.1799T>A, one with CTNNB1 c.133-155
short deletion, three with KRAS c.35G>A, two with KRAS c.38G>A, and eight with one of PIK3CA mutations (c.1624G>A,
c.1633G>A, c.1634A>G, c.1636C>A and c.3140A>G). The detection limitation of mutation frequency was as low as 0.5%,
and all identified mutations were confirmed by independent methods. The CRCPG panel, TA repeats of UGT1A1 gene were
highly polymorphic among populations, and all different repeat (nZ5, 6, 7 and 8) were identified in a single multiplex
reaction. The frequencies of these variants of 24 clinical samples were similar to those of 1,000 Human genome sequencing
databases.
Discussion: High-throughput, cost-effective genotyping assays were established for the detection of clinically CRC relevant
mutations and pharm-related variants. These methods offers high sensitivity and specificity for screening clinically-
actionable mutations, and the panels are compatible with DNA isolated from archival, routinely processed formaline
fixed parrafin embedded (FFPE) tissue and plasma circulating DNA. These cost-effect panels should aid collecting critical
mutation information related to CRC treatment and prognosis, thus contributive to better management of CRC patients on
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